-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Jason Corum
Jason is the web editor with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.
Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation. He spends his free time volunteering with the DC Books to Prisons Project, watching movies and following Ozzie Guillen on Twitter.Latest Posts
How to Drive International Innovation: Scientific American Worldview
Which countries are winning the innovation game? Will the U.S. maintain its leadership position in the future? Have emerging markets lived up to the hype? Which new partnerships are transforming industries? For the fifth year, Scientific American (SA) released their Worldview: A Global Biotechnology Perspective report at the 2013 BIO International Convention in Chicago. Included in this year’s report is the longest list of country rankings that SA has ever compiled and the numbers reveal Read More >
Your Social Media Guide to #BIO2013
The BIO International Convention is the largest global event for the biotechnology industry; it attracts the biggest names in biotech and offers key networking and partnering opportunities. The event is also a great opportunity to connect with the online biotech community and we’re ramping up our social media efforts for the 2013 BIO International Convention, beginning on Monday, April 22 in Chicago. If you’d like to join the online conversation, here are some tips, tricks, Read More >
Small Biotech Companies and China: 5 Keys to Success
Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >
How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >
Celgene CEO on New Multiple Myeloma Drug Approvals
Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >
